next-generation parmodulins targeting PAR1 (Marquette University/Function Therapeutics/Versiti Blood Research Institute/Medical College of Wisconsin)

N/A

Report date: 2025/03/20 15:17:34
NME

Base Information

Drug Namenext-generation parmodulins targeting PAR1 (Marquette University/Function Therapeutics/Versiti Blood Research Institute/Medical College of Wisconsin)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtease-activated receptor-1 modulators
TargetsProtease-activated receptor-1
Therapy Area/IndicationsInflammationThrombosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMarquette University
China Registration ClassN/A

Develop Information

Active CompaniesMarquette UniversityFunction Therapeutics IncVersiti Blood Research Institute +[4] 
Inactive CompaniesN/A
Active IndicationsInflammationThrombosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A